(Q43710972)

English

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.

scientific article published in February 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083543%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083543%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

0 references

plaque psoriasis

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083543%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

J Crowley

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083543%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

J-P Ortonne

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083543%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

J Leu

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083543%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

M Okun

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083543%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

S R Gupta

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083543%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Y Gu

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083543%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

R G Langley

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083543%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

0 references

publication date

1 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083543%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

British Journal of Dermatology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083543%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

164

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083543%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083543%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

434-441

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083543%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10139.X

21 January 2018

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10139.X

21 January 2018

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10139.X

21 January 2018

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10139.X

21 January 2018

The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10139.X

21 January 2018

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10139.X

21 January 2018

Identifiers

10.1111/J.1365-2133.2010.10139.X

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083543%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21083543%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43710972&oldid=2102747060"